Features of C-reactive protein in COVID-19 patients within various period: a cohort study
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
BACKGROUND
Coronavirus disease 2019 (COVID-19) has been declared as a threat to the global. Due to the lack of efficient treatments, indicators were urgently needed during the evolvement of disease to analyze the illness and prognosis and prevent the aggravation of COVID-19.
METHODS
All laboratory confirmed COVID-19 patients hospitalized in Xiangyang No.1 People’s Hospital were included. Patients’ general information, clinical type, CRP value and outcome were collected. CRP values of all patients during disease course from different initial time were analyzed.
RESULTS
The 131 enrolled patients were 50.13±17.13 years old. All cases underwent 724 tests of CRP since symptom onset, 53.18% of the test results were abnormal and the median value was 9.52(2.63-34.10) mg/L. The first median value on the day 8 from exposure onset was 39.08(11.92-47.89) mg/L then fluctuated around it until the day 28. The CRP median increased from 15.93 mg/L to 41.44 mg/L and then decreased to 18.26 mg/L before transformation of severe type, and then increased to 62.25 mg/L on the transforming date. Conversely, the CRP median increased from 56.17 mg/L 102.75 mg/L before transformation of critical type but decreased to 68.68 mg/L on the transforming date. The changes of CRP median over time before death ranged from 77.77 mg/L to 133.52 mg/L.
CONCLUSIONS
CRP increased before symptom onset and substantially increased during the early-to-mid stage (especially early stage), which was different from other virus-infected diseases. The changes of CRP before the transformation of clinical type was inconsistent with the aggravating of illness. And the CRP maintained over 100.00 mg/L prompted poor prognosis.
Article activity feed
-
SciScore for 10.1101/2020.10.26.20219360: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study was approved by the ethics review board of Xiangyang No.1 People’s Hospital (No. 2020GCP012) and registered at the Chinese Clinical Trial Registry as ChiCTR2000031088.
Consent: Informed consent from patients has been exempted since this study does not involve patients’ personal privacy neither incur greater than the minimal risk.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources The reagent was C-reactive protein test kit (Abbott Laboratories), the test instrument is automatic biochemical immunoassay analyzer (Abbott … SciScore for 10.1101/2020.10.26.20219360: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study was approved by the ethics review board of Xiangyang No.1 People’s Hospital (No. 2020GCP012) and registered at the Chinese Clinical Trial Registry as ChiCTR2000031088.
Consent: Informed consent from patients has been exempted since this study does not involve patients’ personal privacy neither incur greater than the minimal risk.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources The reagent was C-reactive protein test kit (Abbott Laboratories), the test instrument is automatic biochemical immunoassay analyzer (Abbott Laboratories ARCHITECT c16200), the normal range of CRP value was 0.00-8.00 mg/L. 2.4 STATISCAL ANALYSIS: All statistical analyses were performed using SPSS 20.0. Abbottsuggested: (Abbott, RRID:SCR_010477)Abbott Laboratoriessuggested: NoneSPSSsuggested: (SPSS, RRID:SCR_002865)All graphs were processed using GraphPad Prism 8.0 and Photoshop CC 14.2 software. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Photoshopsuggested: (Adobe Photoshop, RRID:SCR_014199)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-